Epidermal growth factor receptor inhibitors: current status and future directions.
Chen
Helen X
HX
Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA.
Cleck
Jessica N
JN
Coelho
Rochelle
R
Dancey
Janet E
JE
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D035843:Biomedical Research / Q000379:methods / Q000639:trends; D002626:Chemistry, Pharmaceutical / Q000639:trends; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends*; D015195:Drug Design; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors